FORTITUDE-ALS Is Now Enrolling Participants

FORTITUDE-ALS is a clinical trial which is designed to evaluate whether CK-2127107 has an effect on participants with amyotrophic lateral sclerosis (ALS) and what kind of side effects may occur in these participants taking CK-2127107.   

CK-2127107 is an investigational medicine that is being evaluated as a potential new medicine which could slow the decline of skeletal muscle function in diseases and conditions associated with muscle weakness or fatigue such as ALS.

FORTITUDE-ALS will evaluate the effects of CK-2127107 compared to placebo on muscle performance, including effects on muscles associated with breathing, movement, and speaking, as well as on overall physical function. The main objective of this clinical trial is to evaluate and measure the relationship between different dose levels of CK-2127107 and their potential effects. FORTITUDE-ALS is also designed to evaluate the side effects caused by CK-2127107 that may make it difficult for participants to tolerate taking it.

CK-2127107 is an investigational medicine which means that it is not approved by the FDA or by Health Canada. CK-2127107 is being developed by Cytokinetics, a leader in muscle biology.

FORTITUDE-ALS is currently enrolling participants in both the United States and Canada.

To learn more about how to participate in this clinical trial, please choose a language below: